GILEAD SCIENCES INC
10-Q, EX-27, 2000-11-09
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Previous: GILEAD SCIENCES INC, 10-Q, 2000-11-09
Next: DURA PHARMACEUTICALS INC, 15-12G, 2000-11-09



<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
CONDENSED CONSOLIDATED BALANCE SHEETS AND CONDENSED CONSOLIDATED STATEMENTS OF
OPERATIONS FOUND ON PAGES 3 AND 4 OF THE COMPANY'S FORM 10-Q FOR THE PERIOD
ENDED SEPTEMBER 30, 2000 AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH
FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER> 1,000

<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-2000
<PERIOD-START>                             JAN-01-2000
<PERIOD-END>                               SEP-30-2000
<CASH>                                          43,374
<SECURITIES>                                   249,825
<RECEIVABLES>                                   46,084<F1>
<ALLOWANCES>                                         0
<INVENTORY>                                     19,227
<CURRENT-ASSETS>                               369,840
<PP&E>                                          54,093<F2>
<DEPRECIATION>                                       0
<TOTAL-ASSETS>                                 435,915
<CURRENT-LIABILITIES>                           50,632
<BONDS>                                          3,134
                                0
                                          0
<COMMON>                                            47
<OTHER-SE>                                     376,053
<TOTAL-LIABILITY-AND-EQUITY>                   435,915
<SALES>                                        111,737
<TOTAL-REVENUES>                               140,290
<CGS>                                           26,014
<TOTAL-COSTS>                                  173,957
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                               3,659
<INCOME-PRETAX>                               (24,580)
<INCOME-TAX>                                     1,046
<INCOME-CONTINUING>                           (27,511)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                  (27,511)
<EPS-BASIC>                                     (0.61)
<EPS-DILUTED>                                   (0.61)
<FN>
<F1>RECEIVABLES IS NET OF AN ALLOWANCE FOR DOUBTFUL ACCOUNTS.
<F2>PP&E IS NET OF ACCUMULATED DEPRECIATION.
</FN>


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission